Abstract: Provided are compositions and methods for treating cancer, particularly solid tumors, and cancer metastasis, using micro-RNAs mi R-96 and/or mi R-182.

Abstract: A method for identifying an increased risk of developing ST-Segment Elevation Myocardial Infarction (STEMI) in a subject involves obtaining a platelet-containing plasma sample from the subject; determining a Prostaglandin E2 (PGE2) phenotype of the platelets of the subject; and identifying the subject has having an increased risk of developing STEMI when the subject has a potentiating phenotype, as compared to the risk of a subject having an inhibitory phenotype.

Abstract: A method for identifying an increased risk of developing ST-Segment Elevation Myocardial Infarction (STEMI) in a subject involves obtaining a platelet-containing plasma sample from the subject; determining a Prostaglandin E2 (PGE2) phenotype of the platelets of the subject; and identifying the subject has having an increased risk of developing STEMI when the subject has a potentiating phenotype, as compared to the risk of a subject having an inhibitory phenotype.

Abstract: Provided are compositions and methods for treating cancer, particularly solid tumors, and cancer metastasis, using micro-RNAs mi R-96 and/or mi R-182.

Abstract: Certain neurological disorders are treated with dopamine agonists (e.g. L-Dopa) but these treatments unintentionally cause Levodopa-induced dyskinesias (LIDs) or tardive dyskinesia. An improved treatment is described that treats the patient with both a dopamine agonist and a Smoothened (Smo) agonist or with a dopamine agonist and combination of a Smoothened (Smo) agonist together with Amantadine.

Abstract: The present invention relates to polymorphic binding sites for micro-RNA and to micro-RNA-based cancer diagnosis, cancer therapy and personalized medicine. In particular, the present invention relates to diagnosis, therapy and personalized medicine with the specific miR-515-5p molecule.

Abstract: Provided are methods and kits for determining predisposition to cancer by determining the presence or absence in a heterozygote form of the KLOTHO functional variant. Also provided are methods of designing treatment and treating cancer based on the increased predisposition to the cancer, and to determine the prognosis of a subject diagnosed with cancer.

Abstract: Disclosed are methods of treating neurofibromatosis by administering to a human in need thereof effective amounts of FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof, optionally, in combination with colchicine. Also disclosed are pharmaceutical compositions comprising FTS, or various analogs thereof, or a pharmaceutically acceptable salt thereof; colchicine; and a pharmaceutically acceptable carrier.

Abstract: The NER receptor is a novel member of the steroid hormone receptor superfamily and has been prepared by cDNA cloning from a human osteosarcoma SAOS-2/B10 cell library. The complete sequence of human NER complementary DNA (Seq. ID No. 1), expression systems including a COS stable expression system, the expressed protein (SEQ. ID No. 2) and an assay using the COS expression system are disclosed. The assay may be used to identify agents which activate transcription mediated by the NER receptor, and which are useful for potentiating the activity of a modulator of a G-protein coupled receptor wherein the G-protein coupled receptor is a member of the steroid hormone receptor superfamily.

Abstract: Use of the novel receptor NER TOFA (5-(tetradecyloxy)-2-furan-carboxylic acid) to treat Alzheimer's disease.